日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

帕博利珠单抗联合紫杉醇或固定剂量卡培他滨治疗一线/二线转移性三阴性乳腺癌的 Ib 期临床试验

David B Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L Redmond, Maritza Martel, Zhaoyu Sun, Mary B Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Doroth

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

转移性三阴性乳腺癌接受派姆单抗和紫杉醇或卡培他滨化学免疫治疗期间 T 细胞亚群和克隆库的变化

Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter J Urba, Alison K Conlin, Heather L McArthur, David B Page